ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 1493 • ACR Convergence 2024

    How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline

    Jorge Guerra Sayre1, Andrea Fava2, Daniel Goldman3, Laurence Magder4 and Michelle Petri3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Timonium, MD, 4University of Maryland, Baltimore, Baltimore, MD

    Background/Purpose: Lupus nephritis (LN) occurs in over 50% of SLE patients, contributing significant morbidity and mortality. Despite a generally accepted treatment goal of Complete Renal…
  • Abstract Number: 1798 • ACR Convergence 2024

    CXCL6 Synthesized by Proximal Tubule Cells May Promote Fibrosis in Lupus Nephritis

    Philip Carlucci1, Nalani Sachan2, Andrea Fava3, Brooke Cohen2, Jasmine Shwetar4, Siddarth Gurajala5, Qian Xiao5, Joseph Mears6, Katie Preisinger2, Devyn Zaminski7, Kristina Deonaraine8, Peter Izmirly9, Judith James10, Joel Guthridge10, Wade DeJager11, David Wofsy12, Cynthia Loomis2, Gyles Ward2, Ming Wu13, Chaim Putterman14, Deepak Rao15, Betty Diamond16, Derek Fine17, Jose Monroy-Trujillo17, H Michael Belmont7, William Apruzzese18, Anne Davidson19, Richard Furie20, Paul Hoover21, Celine Berthier22, Maria Dall'Era23, Diane Kamen24, Kenneth Kalunian25, Jennifer Anolik26, Jennifer Barnas27, Arnon Arazi28, Soumya Raychaudhuri29, Nir Hacohen30, Robert Clancy31, Kelly Ruggles32, Michelle Petri33 and Jill Buyon2, and the Accelerating Medicines Partnership in RA/SLE, 1New York University School of Medicine, New York, NY, 2NYU Grossman School of Medicine, New York, NY, 3Johns Hopkins University, Baltimore, MD, 4New York School of Medicine, Ann Arbor, MI, 5Harvard Medical School, Boston, MA, 6Michigan University, Ann Arbor, MI, 7NYU School of Medicine, New York, NY, 8Jacobs School of Medicine, University at Buffalo, Buffalo, NY, 9New York University Grossman School of Medicine, New York, NY, 10Oklahoma Medical Research Foundation, Oklahoma City, OK, 11Oklahoma Medical Research Foundation, Oklahoma City, 12University of California San Francisco, SF, CA, 13Northwell, New York, NY, 14Albert Einstein College of Medicine, Safed, Israel, 15Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 16The Feinstein Institutes for Medical Research, Manhasset, NY, 17Johns Hopkins School of Medicine, Baltimore, MD, 18Brigham and Women's Hospital, Everett, MA, 19Feinstein Institutes for Medical Research, Manhasset, NY, 20Northwell Health, Manhasset, NY, 21Brigham and Women's Hospital, SWAMPSCOTT, MA, 22University of Michigan, Ann Arbor, MI, 23UCSF, Corte Madera, CA, 24Medical University of South Carolina, Charleston, SC, 25University of California San Diego, La Jolla, CA, 26University of Rochester Medical Center, Rochester, NY, 27University of Rochester, Rochester, NY, 28Feinstein Institutes for Medical Research, Melrose, MA, 29Brigham and Women's Hospital, Boston, MA, 30Broad Institute of MIT and Harvard, Boston, MA, 31Columbia University Medical Center, New York, NY, 32NYU Grossman School of Medicine, Brooklyn, NY, 33Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Detection of urinary CXCL6, a member of the IL-8 chemokine family, has been linked to CKD and is a proposed marker of chronic damage…
  • Abstract Number: 2389 • ACR Convergence 2024

    Choroidal Thickness in Active Lupus Nephritis

    Leticia Maria Kolachinski R Brandao1, Lucas Parente de Andrade2, Débora Cordeiro do Rosário3, Paula Letícia De Queiroz e Barbosa4, Francisco Formiga3, Carolina Torres Ribeiro5, Tatiana do Nascimento Pedrosa3, Maria Fernanda Abalem de Sá Carricondo6, Pedro Carlos Carricondo2, Eloisa Bonfa3 and Michelle Remiao Ugolini Lopes3, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Campinas, SP, Brazil, 2Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 4Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, 5Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 6Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil

    Background/Purpose: Lupus choroidopathy was reported to be a marker of severe systemic lupus erythematosus (SLE) activity, commonly associated with nephropathy. However, it remains controversial if…
  • Abstract Number: 0263 • ACR Convergence 2024

    Characteristics and Coinfections of Diffuse Alveolar Hemorrhage in Rheumatic Patients

    Eduardo Briones-García1, Shaul Navarro-Lara2, Marco A Ortiz-Bustamante2, Iris Paola García Herrera3, Carla M Roman-Montes2 and Guillermo A Guaracha-Basañez4, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department., Ciudad de México, Distrito Federal, Mexico, 2Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán., México city, Mexico, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubirán”, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a severe respiratory complication observed in certain rheumatic diseases, such as systemic lupus erythematosus (SLE), ANCA-associated vasculitides (AAV), and…
  • Abstract Number: 0659 • ACR Convergence 2024

    Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial

    Richard Furie1, Jorge A. Ross Terres2, Elsa Martins3, Imran Hassan4, Thomas Schindler3, Jay Garg5, William F. Pendergraft III6, Ana Malvar7 and Brad Rovin8, 1Northwell Health, Manhasset, NY, 2Genentech, Inc,, San Francisco, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc., South San Francisco, CA, 6Genentech, Inc., Chapel Hill, NC, 7Organización Médica de Investigación, Buenos Aires, Argentina, 8The Ohio State University, Columbus, OH

    Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
  • Abstract Number: 1510 • ACR Convergence 2024

    Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort

    Romina Nieto1, Rosana Quintana2, Diana Carolina Fernández Ávila3, Rosa Serrano Morales4, Guillermina Harvey5, Lucia Hernandez6, Karen Roberts7, Nidia Meras8, Cintia Otaduy9, Elisa Novatti10, Valeria Arturi11, Erika S. Palacios Santillan7, Boris Kisluk12, Luciana González Lucero13, Eduardo Kerzberg14, Nicolás Pérez15, Cecilia Pisoni16, Paola Pirruccio17, María E. Crespo18, Ana Carolina Montandon19, Andrese A. Gasparin20, Angela Duarte21, Laissa C. Alves Alvino22, Eloisa Bonfa23, Emily Figuereido Neves24, Lucas Victoria De Oliveira Martins25, Iris Guerra26, Milena Mimica Davet27, Lizeth De La Hoz Rueda28, Andrés Cadena Bonfanti28, Roberth Rivera29, Paola Coral Alvarado30, John Fredy Jaramillo31, José Martínez32, Mario Moreno33, Reyna E. Sánchez Briones34, Mario Pérez Cristóbal35, Eduardo Martin Nares36, Yaneli Juárez-Vicuña37, Yelitza González Bello38, Octavio González39, Leonardo R. Aguilar Rivera40, Margarita Duarte41, Patricia Langjarth42, Wilkerson Pérez Medina41, Armando Calvo43, Teresandris Polanco44, Carina Pizzarossa45, Gonzalo Silveira46, Cristina Reategui47, Graciela Alarcon48, Urbano Sbarigia49, Federico Zazzetti50, Ashley Orillion51, Guillermo Pons-Estel52 and Bernardo Pons-Estel52, 1Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 3Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, 4Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, 5Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, 6Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, 7Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8Hospital Italiano de Córdoba, Córdoba, Spain, 9Hospital Córdoba, Cordoba, Spain, 10Hospital Privado Universitario de Córdoba, Córdoba, Spain, 11Hospital HIGA San Martín, La Plata, Argentina, 12Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, 13Hospital Padilla, Tucumán, Argentina, 14Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, 15Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, 16CEMIC, Buenos Aires, Argentina, 17Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, 18Hospital Señor del Milagro, Salta, Argentina, 19Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, 20Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 21Universidad Federal de Pernambuco, Pernambuco, Brazil, 22Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, 23Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 24Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, 25Universidad Federal São Paulo, São Paulo, SP, Brazil, 26Sección de Reumatología, Hospital del Salvador, Universidad de Chile, Santiago, Chile, 27Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, 28Universidad Simon Bolivar, Barranquilla, Colombia, 29Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, 30Facultad de Medicina, Universidad Nacional de Colombia. Hospital Universitario Nacional, Bogotá, Colombia, 31Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, 32Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, 33Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, 34División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, 35Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, 36Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 37Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, CDMX, Mexico, 38Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, 39Hospital Central Dr. Ignacio Morones Prieto, SLP, Mexico, 40Servicio de Reumatología (CEAR). Hospital Universitario "Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Nuevo Leon, Mexico, 41Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, 42Hospital de Clínicas I, Asunción, Paraguay, 43Hospital Cayetano Heredia, San Martin de Porres, Peru, 44Hospital Docente Padre Billini, Santo Domingo, Dominica, 45Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, 46Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, 47Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, 48The University of Alabama at Birmingham, Birmingham, AL, 49Johnson & Johnson Innovative Medicine, Brussels, Belgium, 50Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 51Johnson & Johnson Innovative Medicine, Spring House, PA, PA, 52Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina

    Background/Purpose: To evaluate health-related quality of life (HRQoL) in patients with active lupus nephritis (LN) at baseline and 12 months after treatment in relationship to…
  • Abstract Number: 1802 • ACR Convergence 2024

    Heterogeneous Neutrophil Subsets Infiltrate Glomeruli of Lupus Nephritis Patients and Are Elevated in the Kidneys and Urine of Sunlight-induced Nephritis Flares

    Noelle Kosarek1, Joshua Skydel2, Alecia Roy3, Fred Kolling1, Lucas Salas1, Christopher Burns4, Andrea Fava5 and Sladjana Skopelja-Gardner1, 1Geisel School of Medicine at Dartmouth, Lebanon, 2Dartmouth Hitchcock Medical Center, Lebanon, 3Dartmouth College, Lebanon, NH, 4Dartmouth Hitchcock Medical Center, Lebanon, NH, 5Divison of Rheumatology, Johns Hopkins University, Baltimore, MD

    Background/Purpose: Up to ~60% of SLE patients in North America will develop kidney disease, lupus nephritis (LN), one of the main contributors to disease morbidity…
  • Abstract Number: 2392 • ACR Convergence 2024

    Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study

    Güllü Sandal Uzun1 and David Isenberg2, 1University College London, London, England, United Kingdom, 2University College London, London, United Kingdom

    Background/Purpose: Systemic lupus erythematosus (SLE) and idiopathic inflammatory myositis (IIM)  are chronic, potentially severe autoimmune diseases, that may affect many organs/ systems. In this study, we…
  • Abstract Number: 0324 • ACR Convergence 2024

    Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials

    Daniel Nunez1, Jenell Volkov1, Jason Stadanlick1, Zachary Vorndran1, Alexandra Ellis1, Mallorie Werner1, Justin Cicarelli1, Jazmean Williams1, Fatemeh Nezhad1, Thomas Furmanak2, Quynh Lam1, Rebecca Estremera1, Yvonne White1, Jonathan Hogan1, Claire Miller1, Tahseen Mozaffar3, Saira Sheikh4, David Chang1 and Samik Basu1, 1Cabaletta Bio, Philadelphia, PA, 2Cabaletta Bio - Philadelphia, PA, Philadelphia, PA, 3The University of California, Irvine, Orange, CA, 4University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
  • Abstract Number: 0660 • ACR Convergence 2024

    Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis

    Shivani Garg1, Brad Rovin2, Brad Astor1, Tripti Singh1, Lexie Kolton1, Callie Saric1, S. Sam Lim3 and Christie Bartels4, 1University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 2The Ohio State University, Columbus, OH, 3Emory University, Atlanta, GA, 4University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone in treatment of systemic lupus erythematosus (SLE), yet its role in preventing kidney function decline in lupus nephritis (LN)…
  • Abstract Number: 1511 • ACR Convergence 2024

    Lupus Nephritis and Response to Treatment in Latin America

    Rosana Quintana1, Romina Nieto2, Diana Carolina Fernández Ávila3, Rosa Serrano Morales4, Guillermina Harvey5, Lucia Hernandez6, Karen Roberts7, Marina Scolnik8, Carmen Funes Soaje9, Paula Alba10, Veronica Saurit11, Mercedes Garcia12, Guillermo Berbotto13, VERONICA BELLOMIO14, Wilfredo Patiño Grageda15, Graciela Gómez16, Cecilia Pisoni17, Ana Malvar18, Vicente Juarez19, Nilzio A. Da Silva20, ODIRLEI MONTICIELO21, Henrique Ataide Mariz22, Francinne Machado Ribeiro23, Eduardo Borba24, Luciana Parente24, Edgard Torres25, Oscar Neira26, Loreto Massardo27, Gustavo Aroca Martínez28, Carlos A. Cañas Davila29, Gerardo Quintana López30, Carlos Enrique Toro-Gutierrez31, Mario Moreno32, Andres Zuñiga33, Miguel Angel Saavedra Salinas34, Margarita Portela Hernandez35, Hilda Fragoso-Loyo36, Luis H. Silveira Torre37, Ignacio García De La Torre38, Carlos Abud Mendoza39, Marcos Fonseca Hernández40, Jorge Esquivel-Valerio41, Isabel Acosta Colman42, Jhonatan Losanto43, Claudia Selene Mora Trujillo44, Katiuzka Zuñiga Corrales45, Roberto Muñoz Louis46, Martin Rebella47, Álvaro Danza48 Manuel Ugarte-Gil49, Graciela Alarcon50, Urbano Sbarigia51, Federico Zazzetti52, Ashley Orillion53, Guillermo Pons-Estel54 and Bernardo Pons-Estel54, 1Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, 3Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, 4Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, 5Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, 6Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, 7Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 9Hospital Italiano, Cordoba, Argentina, 10Hospital Cordoba, Cordoba, Spain, 11hospital privado universitario de cordoba, Córdoba, Argentina, 12HIGA San Martin, La Plata, Argentina, 13Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, ROSARIO, Argentina, 14Hospital Padilla, San Miguel de Tucumán, Argentina, 15Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, 16Instituto de Investigaciones Médicas Alfredo Lanari, Autónoma de Buenos Aires, Argentina, 17CEMIC, Buenos Aires, Argentina, 18Organización Médica de Investigación, Buenos Aires, Argentina, 19Hospital Señor del Milagro, Salta, Salta, Argentina, 20Hospital das Clinicas, Universidad Federal de Goias, Goias, Goias, Brazil, 21HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, 22Universidad Federal de Pernambuco, Pernambuco, Brazil, 23Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, 24Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 25Universidad Federal São Paulo, São Paulo, SP, Brazil, 26Hospital del Salvador, Santiago de Chile, Chile, 27Facultad de Medicina y Ciencia, Universidad San Sebastián, San Sebastián, Chile, 28Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, 29Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, 30Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, 31Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, 32Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, 33Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, 34División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, 35Departamento de Reumatología del Hospital de especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (IMSS), Mexico, Mexico, 36Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, 37Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 38Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, 39Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, 40Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico, 41Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, 42Hospital de Clínicas I, Asunción, Paraguay, 43Hospital de Clínicas I, San Lorenzo, Paraguay, 44Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, 45Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 46Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, 47Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, 48Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, 49Universidad Cientifica del Sur, Lima, Lima, Peru, 50The University of Alabama at Birmingham, Birmingham, AL, 51Johnson & Johnson Innovative Medicine, Brussels, Belgium, 52Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 53Johnson & Johnson Innovative Medicine, Spring House, PA, PA, 54Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina

    Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…
  • Abstract Number: 1803 • ACR Convergence 2024

    Genetics of eGFR Variability as a Proxy for Lupus Nephritis in Patients with Systemic Lupus Erythematosus

    Magdalena Riedl Khursigara1, Nicholas Gold2, Thai-Son Tang3, JingJing Cao4, Daniela Dominguez4, Marisa Klein-Gitelman5, Dafna Gladman6, Daniel Goldman7, Elizabeth Harvey4, Mariko Ishimori8, Caroline Jefferies9, Diane Kamen10, Sylvia Kamphuis11, Andrea Knight12, Chia-Chi Lee13, Deborah Levy2, Damien Noone4, Karen Onel14, Christine Peschken15, Michelle Petri7, Janet Pope16, Eleanor Pullenayegum4, Earl Silverman17, Zahi Touma18, Murray Urowitz19, Daniel Wallace20, Joan Wither21 and Linda Hiraki2, and Systemic Lupus Erythematosus Collaborative Clinics (SLICC), 1University of Toronto, Cambridge, MA, 2The Hospital for Sick Children, Toronto, ON, Canada, 3University of Toronto, Mississauga, ON, Canada, 4The Hospital for Sick Children, Toronto, Canada, 5Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 6University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 7Johns Hopkins University School of Medicine, Timonium, MD, 8Cedars-Sinai Health System, Los Angeles, CA, 9Cedars-Sinai Medical Center, Beverly Hills, CA, 10Medical University of South Carolina, Charleston, SC, 11Erasmus University Medical Center, Rotterdam, Netherlands, 12Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 13Cedars-Sinai Medical Center, Los Angeles, CA, 14HSS, New York, NY, 15University of Manitoba, Winnipeg, MB, Canada, 16University of Western Ontario, London, ON, Canada, 17Silverman, Toronto, ON, Canada, 18University of Toronto, Toronto, ON, Canada, 19Self employed, Toronto, ON, Canada, 20Cedars Sinai Medical Center, Studio City, CA, 21University Health Network, Toronto, ON, Canada

    Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). We performed genome wide association studies (GWAS)…
  • Abstract Number: 2395 • ACR Convergence 2024

    Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)

    Antônio Silaide De Araújo-Júnior1, Emília Sato2, Alexandre Wagner Silva de Souza1, Fábio Jennings1, Gianna Mastroianni Kirsztajn3, Ricardo Sesso3 and Edgard Reis Neto4, 1Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil., São Paulo, SP, Brazil, 2Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, 3Division of Nephrology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil., São Paulo, SP, Brazil, 4Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil

    Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), and kidney biopsy is the gold…
  • Abstract Number: 0445 • ACR Convergence 2024

    Evaluating Clinical Reasoning in Randomized Surveys of Lupus Nephritis and Preeclampsia Pregnancy Case Workups: A Clinical Conundrum

    Liya Stolyar1, Sadaf Sediqi2, Richard Lafayette3, Maurice Druzin4, Saadiya Hawa5, Amanda Moyer6, Yashaar Chaichian2 and Julia Simard2, 1Palo Alto VA Medical Center/Stanford, Stanford, CA, 2Stanford School of Medicine, Stanford, CA, 3Stanford, Stanford, CA, 4Stanford University School of Medicine, Stanford, CA, 5Weiss Memorial Hospital, Chicago, IL, 6Stanford University, San Bruno, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) pregnancy is associated with a heightened risk of adverse pregnancy outcomes, including preeclampsia. Distinguishing preeclampsia from lupus nephritis (LN) presents…
  • Abstract Number: 0661 • ACR Convergence 2024

    Validity, Reliability and Responsiveness of Lupus Impact Tracker and LupusPRO: AURORA Trial

    Meenakshi Jolly1, Matt Truman2, Ronald Flauto3 and Kathryn Dao4, and AURORA, 1Rush University Medical Center, Chicago, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals, Rockville, MD, 4Aurinia Pharmaceuticals, Dallas

    Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology